文献速递白血病

信号突变抵消老年AML患者NPM1突变 favorable 效应

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.
PubMed 文献 · Am J Hematol · 2026-07-02

两项独立队列研究评估≥60岁接受HMA+VEN治疗的AML患者中NPM1突变伴或不伴信号基因突变的预后意义。结果显示信号突变可抵消NPM1突变的有利影响,尤其在真实世界队列中NPM1伴信号共突变者OS显著缩短。

要点

  • NPM1突变在HMA+VEN治疗的老年AML中并非总是有利。
  • 伴FLT3-ITD、NRAS或KRAS共突变时NPM1突变预后不良。
  • 需前瞻性试验探索联合治疗改善该高危亚组。

核心结论

  • 信号基因突变抵消了老年AML患者接受HMA+VEN治疗时NPM1突变的有利影响。

研究设计与样本

  • 研究评估两个独立队列中≥60岁ELN 2024有利或中危AML接受HMA+VEN治疗的患者。
  • 队列1为学术环境322例患者,队列2为社区真实世界816例患者。

主要发现

  • 队列1中NPM1突变(n=61)对比野生型中位OS为53.05 vs 17.03个月(p=0.10)。
  • 队列1多变量分析中信号突变在NPM1突变亚组内无独立预后意义。
  • 队列2中NPM1突变(n=124)对比野生型中位OS为15.3 vs 14.4个月(p=0.03)。
  • 队列2多变量分析中NRAS、KRAS和FLT3-ITD为独立不良预后因素。
  • 队列2中NPM1伴信号共突变对比无共突变中位OS为9.4 vs 31.6个月(p=0.001)。

临床怎么用

  • 对老年AML患者接受HMA+VEN治疗前应评估NPM1及信号基因突变状态。
  • NPM1突变伴FLT3-ITD、NRAS或KRAS共突变者应视为高危并考虑强化或联合治疗。

局限性

  • 两个队列均为回顾性分析,可能存在选择偏倚。
  • 需前瞻性临床试验验证联合治疗在该高危亚组中的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Frameshift mutations in exon 12 of nucleophosmin 1 (NPM1 mut) are among the most common mutations in acute myeloid leukemia (AML) and have historically been considered favorable-risk in the absence of FLT3-ITD. In the European LeukemiaNet (ELN) 2024 risk-classification for patients treated with hypomethylating agents plus venetoclax (HMA + VEN), NPM1 mut is not considered favorable when co-occurring with signaling gene (SG) mutations (i.e., FLT3-ITD, NRAS, KRAS). However, due to limited numbers in the original analysis, the prognostic impact of SG mutations in NPM1-mutant AML remains unclear. We evaluated the prognostic significance of NPM1 mut with and without SG mutations in two independent cohorts of patients ≥ 60 years with ELN 2024 favorable- or intermediate-risk AML treated with HMA + VEN. Cohort 1 included 322 patients treated in the academic setting. NPM1 mut (n = 61) was associated with a nonsignificantly longer overall survival (OS) compared to NPM1 wild-type (NPM1 wt) (median, 53.05 vs. 17.03 months, p = 0.10). In multivariable analysis (MVA), SG mutations were not independently prognostic within the NPM1 mut subgroup. Cohort 2 included 816 patients from a real-world community-treated cohort. NPM1 mut (n = 124) had a longer OS compared with NPM1 wt (median, 15.3 vs. 14.4 months, p = 0.03). In MVA, NRAS, KRAS, and FLT3-ITD were independent unfavorable prognostic factors; NPM1 mut with, compared to without, SG co-mutation had a shorter OS (median, 9.4 vs. 31.6 months, p = 0.001). These findings suggest SG mutations negate the favorable impact of NPM1 mut in older patients treated with HMA + VEN. Prospective clinical trials are needed to investigate the use of combination therapies to improve outcomes in this high-risk subgroup.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Hoff FW, Zeidner JF, Torlapati G, et al. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026. PMID: 42393840. doi:10.1002/ajh.70419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。